Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus GOZELLIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus GOZELLIX.
AZSTARYS vs GOZELLIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
GOZELLIX (relugolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It competitively binds to GnRH receptors in the anterior pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing ovarian estrogen and testicular testosterone production.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
250 mg subcutaneously once monthly.
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Terminal elimination half-life: 14–16 hours in healthy adults; prolonged in renal impairment (up to 30 hours in ESRD).
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Primarily renal (approx. 80%) as unchanged drug; biliary/fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant